- Home
- PEB vs RCUS Comparison
PEB vs RCUS Comparison
Compare PEB & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEB
- RCUS
- Stock Information
- Founded
- PEB 2009
- RCUS 2015
- Country
- PEB United States
- RCUS United States
- Employees
- PEB N/A
- RCUS N/A
- Industry
- PEB Real Estate Investment Trusts
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- PEB Real Estate
- RCUS Health Care
- Exchange
- PEB Nasdaq
- RCUS Nasdaq
- Market Cap
- PEB 1.5B
- RCUS 1.4B
- IPO Year
- PEB 2009
- RCUS 2018
- Fundamental
- Price
- PEB $12.20
- RCUS $15.72
- Analyst Decision
- PEB Hold
- RCUS Buy
- Analyst Count
- PEB 5
- RCUS 12
- Target Price
- PEB $14.30
- RCUS $34.50
- AVG Volume (30 Days)
- PEB 1.7M
- RCUS 932.9K
- Earning Date
- PEB 11-07-2024
- RCUS 11-06-2024
- Dividend Yield
- PEB 0.33%
- RCUS N/A
- EPS Growth
- PEB N/A
- RCUS N/A
- EPS
- PEB N/A
- RCUS N/A
- Revenue
- PEB $1,449,797,000.00
- RCUS $263,000,000.00
- Revenue This Year
- PEB N/A
- RCUS $112.97
- Revenue Next Year
- PEB $3.28
- RCUS N/A
- P/E Ratio
- PEB N/A
- RCUS N/A
- Revenue Growth
- PEB 3.15
- RCUS 119.17
- 52 Week Low
- PEB $11.65
- RCUS $13.50
- 52 Week High
- PEB $16.65
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- PEB 42.63
- RCUS 43.78
- Support Level
- PEB $12.49
- RCUS $15.03
- Resistance Level
- PEB $12.90
- RCUS $18.98
- Average True Range (ATR)
- PEB 0.45
- RCUS 1.02
- MACD
- PEB 0.00
- RCUS -0.04
- Stochastic Oscillator
- PEB 25.00
- RCUS 20.07
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,924 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.